A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Here we describe the development of a two-step chromatography process based on the use of ion-exchange resins for the purification of recombinant adeno-associated virus (rAAV) serotypes-2 and-5. In vitro and in vivo results demonstrate that this method, which does not require any prepurification step of the cell lysate, can be applied to obtain highly pure rAAV2 and rAAV5 stocks. As such,this procedure can be easily transferred in vector cores and also scaled up, allowing the direct comparison of these two, and potentially other, AAV serotypes in large animal models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“Recently, recombinant vectors derived from other AAV serotypes, such as AAV5, AAV-4, and AAV1, have also been developed and shown to display, in some tissues, a different tropism and/or transduction efficiency compared with rAAV2 particles [2–5].”
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273
Grimm, D., Kern, A., Pawlita, M., Ferrari, F. K., Samulski, R. J., & Kleinschmidt, J. A. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300946 · Cited by 195
Bantel-Schaal, U., Delius, H., Schmidt, R., & zur Hausen, H. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.939-947.1999 · Cited by 128
Research works printed but not linked: 29
- Snyder, 1999, Adeno-associated virus-mediated gene delivery, J. Gene Med, 1, 166, 10.1002/(SICI)1521-2254(199905/06)1:3<166::AID-JGM34>3.0.CO;2-Z · DOI · Paper page
- Rabinowitz, 2002, Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J. Virol, 76, 791, 10.1128/JVI.76.2.791-801.2002 · DOI · Paper page
- Zabner, 2000, Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer, J. Virol, 74, 3852, 10.1128/JVI.74.8.3852-3858.2000 · DOI · Paper page
- Grimm, 1998, Novel tools for production and purification of recombinant adeno-associated virus vectors, Hum. Gene Ther, 9, 2745, 10.1089/hum.1998.9.18-2745 · DOI · Paper page
- Clark, 1995, Cell lines for the production of recombinant adeno-associated virus, Hum. Gene Ther, 6, 1329, 10.1089/hum.1995.6.10-1329 · DOI · Paper page
- Inoue, 1998, Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors, J. Virol, 72, 7024, 10.1128/JVI.72.9.7024-7031.1998 · DOI · Paper page
- Liu, X., Voulgaropoulou, F., Chen, R., Johnson, P. R., and Clark, K. R.2000. Selective rep-cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther.2: 394–403, · DOI · Paper page
- Chadeuf, 2000, Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome, J. Gene Med, 2, 260, 10.1002/1521-2254(200007/08)2:4<260::AID-JGM111>3.0.CO;2-8 · DOI · Paper page
- Gao, 2000, Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo, Hum. Gene Ther, 11, 2079, 10.1089/104303400750001390 · DOI · Paper page
- Mathews, 2002, Recombinant adeno-associated viral vector production using stable packaging and producer cell lines, Methods Enzymol, 346, 393, 10.1016/S0076-6879(02)46068-5 · DOI
- Zolotukhin, 1999, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther, 6, 973, 10.1038/sj.gt.3300938 · DOI · Paper page
- Tamayose, 1996, A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography, Hum. Gene Ther, 7, 507, 10.1089/hum.1996.7.4-507 · DOI · Paper page
- Debelak, 2000, Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2, J. Chromatogr, B 740, 195, 10.1016/S0378-4347(00)00100-6 · DOI
- Auricchio, A., O'Connor, E., Hildinger, M., and Wilson, J. M.2001. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol. Ther.4: 372–374, · DOI · Paper page
- Drittanti, 2001, Optimised helper virus-free production of high-quality adeno-associated virus vectors, J. Gene Med, 3, 59, 10.1002/1521-2254(2000)9999:9999<::AID-JGM152>3.0.CO;2-U · DOI · Paper page
- O'Riordan, 2000, Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV), J. Gene Med, 2, 444, 10.1002/1521-2254(200011/12)2:6<444::AID-JGM132>3.0.CO;2-1 · DOI
- Anderson, 2000, A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction, J. Virol. Methods, 85, 23, 10.1016/S0166-0934(99)00150-0 · DOI
- Clark, 1999, Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum. Gene Ther, 10, 1031, 10.1089/10430349950018427 · DOI · Paper page
- Potter, 2002, Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors, Methods Enzymol, 346, 413, 10.1016/S0076-6879(02)46069-7 · DOI
- Auricchio, 2001, Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column, Hum. Gene Ther, 12, 71, 10.1089/104303401450988 · DOI · Paper page
- Chiorini, 1999, Cloning and characterization of adeno-associated virus type 5, J. Virol, 73, 1309, 10.1128/JVI.73.2.1309-1319.1999 · DOI · Paper page
- Kaludov, 2001, Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity, J. Virol, 75, 6884, 10.1128/JVI.75.15.6884-6893.2001 · DOI · Paper page
- Zhang, 1994, Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation of the cytokeratin network, J. Virol, 68, 2544, 10.1128/JVI.68.4.2544-2555.1994 · DOI
- Vellekamp, 2001, Empty capsids in column-purified recombinant adenovirus preparations, Hum. Gene Ther, 12, 1923, 10.1089/104303401753153974 · doi:10.1089/104303401753153974
- Bantel-Schaal, 2002, Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment, J. Virol, 76, 2340, 10.1128/jvi.76.5.2340-2349.2002 · DOI · Paper page
- Salvetti, 1998, Factors influencing recombinant adeno-associated virus production, Hum. Gene Ther, 9, 695, 10.1089/hum.1998.9.5-695 · DOI · Paper page
- Graham, F. L., and Prevec, L.1991. Manipulation of adenovirus vectors. In Gene Transfer and ProtocolE. J. Murray, Ed., Vol. 7, pp. 109–128. Humana Press, Clifton, NJ. · DOI · Paper page
- Samulski, R. J., Chang, L. S., and Shenk, T.1989. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63: 3822–3828. · DOI · Paper page
- Favre, 2000, Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle, Gene Ther, 7, 1417, 10.1038/sj.gt.3301256 · DOI
Cited by
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Grimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M., Alvira, M., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 334
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Smith, R. H., Levy, J. R., & Kotin, R. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.128 · Cited by 261
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
Manufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
“Mammalian stable cell lines infected with Ad were actually the first system to provide a scalable upstream process for manufacturing of purified rAAV particles.(34,35,52,53) Moreover, a HeLa-based stable cell line was used for production of the first AAV product administrated in humans in a clinical trial for the trea…”
MethodAllay, J. A., Sleep, S., Long, S., Tillman, D. M., Clark, R., Carney, G., Fagone, P., McIntosh, J. H., Nienhuis, A. W., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.202 · Cited by 152
Wang, C., Mulagapati, S. H. R., Chen, Z., Du, J., Zhao, X., Xi, G., Chen, L., Linke, T., Gao, C., Schmelzer, A. E., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.006 · Cited by 105
Lock, M., Alvira, M. R., & Wilson, J. M. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.217 · Cited by 99
Urabe, M., Xin, K.-Q., Obara, Y., Nakakura, T., Mizukami, H., Kume, A., Okuda, K., & Ozawa, K. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.024 · Cited by 94
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Fu, X., Chen, W.-C., Argento, C., Clarner, P., Bhatt, V., Dickerson, R., Bou-Assaf, G., Bakhshayeshi, M., Lu, X., Bergelson, S., et al. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.088 · Cited by 77
Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9
Tomono, T., Hirai, Y., Okada, H., Miyagawa, Y., Adachi, K., Sakamoto, S., Kawano, Y., Chono, H., Mineno, J., Ishii, A., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.015 · Cited by 55
Werling, N. J., Satkunanathan, S., Thorpe, R., & Zhao, Y. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.013 · Cited by 53
The function of DNA binding protein nucleophosmin in AAV replication
Satkunanathan, S., Thorpe, R., & Zhao, Y. (2017) · Virology · doi:10.1016/j.virol.2017.07.007 · Cited by 24
Metadata
- Authors
- Brument, N., Morenweiser, R., Blouin, V., Toublanc, E., Raimbaud, I., Chérel, Y., Folliot, S., Gaden, F., Boulanger, P., Kroner-Lux, G., Moullier, P., Rolling, F., & Salvetti, A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 6
- Issue
- 5
- Pages
- 678-686
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4245087155
- Cited by
- 87
- References
- 6
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 5089 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.